Zoetis Inc. $ZTS Shares Acquired by Oddo BHF Asset Management Sas

Oddo BHF Asset Management Sas lifted its holdings in shares of Zoetis Inc. (NYSE:ZTS) by 28.8% during the 4th quarter, Holdings Channel reports. The firm owned 47,469 shares of the company’s stock after buying an additional 10,622 shares during the period. Oddo BHF Asset Management Sas’ holdings in Zoetis were worth $5,973,000 as of its most recent SEC filing.

Several other hedge funds have also made changes to their positions in the business. Nordea Investment Management AB raised its holdings in Zoetis by 79.2% in the fourth quarter. Nordea Investment Management AB now owns 4,932,787 shares of the company’s stock valued at $622,222,000 after acquiring an additional 2,179,578 shares in the last quarter. Seilern Investment Management Ltd raised its holdings in Zoetis by 361.2% in the fourth quarter. Seilern Investment Management Ltd now owns 333,465 shares of the company’s stock valued at $41,957,000 after acquiring an additional 261,155 shares in the last quarter. Assenagon Asset Management S.A. raised its holdings in Zoetis by 134.4% in the fourth quarter. Assenagon Asset Management S.A. now owns 1,631,619 shares of the company’s stock valued at $205,290,000 after acquiring an additional 935,432 shares in the last quarter. Pincus Capital Management LP acquired a new stake in Zoetis in the fourth quarter valued at approximately $2,109,000. Finally, AE Wealth Management LLC raised its holdings in Zoetis by 71.3% in the fourth quarter. AE Wealth Management LLC now owns 144,531 shares of the company’s stock valued at $18,185,000 after acquiring an additional 60,167 shares in the last quarter. Institutional investors and hedge funds own 92.80% of the company’s stock.

Analysts Set New Price Targets

ZTS has been the topic of several analyst reports. Weiss Ratings cut shares of Zoetis from a “sell (d+)” rating to a “sell (d)” rating in a report on Friday. Morgan Stanley reaffirmed an “overweight” rating and issued a $115.00 target price on shares of Zoetis in a report on Friday, May 15th. Argus reaffirmed a “hold” rating on shares of Zoetis in a report on Wednesday, May 27th. BTIG Research reissued a “buy” rating and set a $160.00 price objective on shares of Zoetis in a report on Thursday, February 26th. Finally, JPMorgan Chase & Co. cut their price objective on shares of Zoetis from $190.00 to $130.00 and set an “overweight” rating on the stock in a report on Friday, May 8th. Six investment analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Hold” and an average price target of $133.92.

Insiders Place Their Bets

In related news, Director Michael B. Mccallister bought 3,000 shares of the firm’s stock in a transaction on Monday, May 11th. The shares were bought at an average cost of $77.76 per share, for a total transaction of $233,280.00. Following the transaction, the director owned 24,524 shares of the company’s stock, valued at approximately $1,906,986.24. This trade represents a 13.94% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Paul Bisaro bought 2,000 shares of the firm’s stock in a transaction on Wednesday, May 13th. The shares were bought at an average price of $75.88 per share, for a total transaction of $151,760.00. Following the completion of the transaction, the director directly owned 27,862 shares in the company, valued at approximately $2,114,168.56. This represents a 7.73% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. In the last ninety days, insiders have purchased 11,650 shares of company stock worth $886,384. Corporate insiders own 0.22% of the company’s stock.

Zoetis Stock Performance

Shares of ZTS opened at $79.95 on Tuesday. The company’s 50 day simple moving average is $96.18 and its 200-day simple moving average is $113.83. Zoetis Inc. has a 12-month low of $72.38 and a 12-month high of $166.77. The company has a current ratio of 3.15, a quick ratio of 1.91 and a debt-to-equity ratio of 2.80. The firm has a market cap of $33.52 billion, a PE ratio of 13.26, a price-to-earnings-growth ratio of 1.24 and a beta of 0.75.

Zoetis (NYSE:ZTS) last announced its quarterly earnings data on Thursday, May 7th. The company reported $1.53 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.60 by ($0.07). The firm had revenue of $2.26 billion during the quarter, compared to analyst estimates of $2.30 billion. Zoetis had a net margin of 27.80% and a return on equity of 66.85%. The business’s quarterly revenue was up 2.9% compared to the same quarter last year. During the same period in the prior year, the firm posted $1.48 earnings per share. Zoetis has set its FY 2026 guidance at 6.850-7.000 EPS. As a group, equities analysts predict that Zoetis Inc. will post 6.88 EPS for the current year.

Zoetis Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 1st. Shareholders of record on Monday, July 20th will be given a dividend of $0.53 per share. This represents a $2.12 annualized dividend and a dividend yield of 2.7%. The ex-dividend date is Monday, July 20th. Zoetis’s payout ratio is presently 35.16%.

Zoetis Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.